 | Regeneron Pharmaceuticals, Inc. 777 Old Saw Mill River Road Tarrytown, NY 10591-6707 | Phone 914 847 7000 www.regeneron.com | ||
June 12, 2014
Via EDGAR
Mr. Jim B. Rosenberg
Senior Assistant Chief Accountant
U.S. Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, D.C. 20549
Re: | Regeneron Pharmaceuticals, Inc. |
Form 10-K for the Fiscal Year Ended December 31, 2013 | |
Filed February 13, 2014 | |
File No. 000-19034 | |
Dear Mr. Rosenberg:
Regeneron Pharmaceuticals, Inc. (the “Company”) acknowledges receipt of oral comments provided by the staff of the Securities and Exchange Commission on June 3, 2014, with respect to the above-referenced Form 10-K. The Company subsequently corresponded with Scott Wuenschell on June 9, 2014, who kindly granted the Company’s request for a five business day extension. Accordingly, the Company plans to expand its explanations to supplement its initial responses in its letter dated April 30, 2014, on or before June 24, 2014.
If you have any questions regarding the foregoing, please contact me at (914) 847-7270.
Very truly yours,
REGENERON PHARMACEUTICALS, INC.
/s/ Robert E. Landry
Robert E. Landry
Senior Vice President, Finance and
Chief Financial Officer
cc: Securities and Exchange Commission
Scott Wuenschell
Joel Parker